Sustained Minimal Disease Activity With Upadacitinib and Abrocitinib in Moderate‐to‐Severe Atopic Dermatitis: A 104‐Week, Real‐World, Retrospective Study

International Journal of Dermatology · Published 2026-06-25 · DOI 10.1111/ijd.70558

Authors (6)

Ioannis‐Alexios Koumprentziotis, Aikaterini Tsiogka, Ileana‐Afroditi Kleidona, Aristeidis Vaiopoulos, Alexander Stratigos, Stamatios Gregoriou

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Koumprentziotis, I., Tsiogka, A., Kleidona, I., et al. (2026). Sustained Minimal Disease Activity With Upadacitinib and Abrocitinib in Moderate‐to‐Severe Atopic Dermatitis: A 104‐Week, Real‐World, Retrospective Study. International Journal of Dermatology. https://doi.org/10.1111/ijd.70558

Related articles